Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
News
Ashvattha Therapeutics to Present at Biotech Showcase 2023
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company…
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) — Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology…
AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVEO Stockholders Vote “FOR”…
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio…
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic…
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
All three sickle cell disease participants treated with briquilimab successfully engrafted with neutrophil engraftment within…
Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Athenex Announces MHRA Decision on Oral Paclitaxel
MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control…
Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) announced today…
Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company…
Alphalyse and Bavarian Nordic A/S significantly shorten the time necessary to document HCP impurities in COVID-19 vaccine candidate for Phase 3 clinical trial – through world’s first MS-based HCP analysis under GMP conditions
ODENSE, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) — Alphalyse has performed the world’s first GMP-certified…
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage…
Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company…
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage…
Dante Genomics to present at the 41st Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics…
Nubeva Announces Projected Cash Flow Positive Operations in 2023
New Seven-Figure Contract Expected to Move Company Into The Black SAN JOSE, Calif., Jan. 03,…